A Water-Free ITIES: Ionic Liquid/Oil Interface for Base Metal Nanostructure Formation - Zn Case

Reductive metal deposition at the interface between two immiscible electrolyte solutions (ITIES), the oil/water interface, is an attractive methodology to produce metal nanostructures. However, the metals that can be deposited are limited to noble metals; otherwise, water molecules are reduced. Herein, a method to overcome this limitation by utilizing a novel water-free ITIES between a hydrophilic ionic liquid and oil was introduced. As proof-of-concept experiments, the reductive deposition of zinc, a base metal with a standard redox potential more negative than that of water, was successfully realized at the ionic liquid/oil interface. The morphology of the zinc nanostructures was investigated, and the reaction mechanism was discussed, in which the electron transfer and ion transfer reactions across the interface simultaneously occurred to maintain the electroneutrality of the liquids

NASDA satellite mission operation system and operations

NASDA has recently developed a new tracking and control system as a basis for future satellite mission operation. It is named type-I Space Operations and Data Systems (type-I SODS). The software of this system is separated into three parts: operation and control system, network system, and support and information system. The operation control system treats telemetry and command operations. The network system controls the communication line and ground station equipments to connect the satellite and the operation control system. The support and information system provides to other systems necessary information. JERS-1 which was launched in February of this year is the first satellite operated by type-l SODS. We explain the architecture and operation methods of this system using JERS-1 mission operations

Effect of vasodilators in patient with pulmonary hypertension associated with hemolytic anemia

AbstractPulmonary arterial hypertension (PAH) has been described to associate with hemolytic anemia in updated clinical classification of pulmonary hypertension. A 56-year-old woman, diagnosed with warm antibody autoimmune hemolytic anemia (AIHA), was treated with oral corticosteroids at the Department of Hematology, Osaka University Hospital for 30 years. Her AIHA worsened 3 months before the admission, and she was treated with rituximab and cyclosporine in combination with prednisolone. Soon after she left the hospital, she developed dyspnea on effort and leg edema, therefore she was re-admitted to the Department of Cardiovascular Medicine. Echocardiogram and cardiac catheterization demonstrated PAH associated with AIHA. She was treated with three types of vasodilatory agents, resulting in an improvement in pulmonary arterial pressure and pulmonary vascular resistance after 6 weeks. A few weeks after she left the hospital, her hemolytic anemia became in remission without intensifying AIHA therapy, and did not worsen for a year of follow-up. Although corticosteroids are the first-line treatment for AIHA, medications for PAH should be considered when the first-line therapy for AIHA failed to improve PAH